Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 16/20 | 0.44 |
| ▸ | DRD1 | P21728 | 16/20 | 0.44 |
| ▸ | DRD5 | P21918 | 14/20 | 0.44 |
| ▸ | DRD4 | P21917 | 9/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 11/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.35 |
| ▸ | BAD | Q92934 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7527997 | 0.80 | DRD2 (0.49) | DRD2DRD1DRD5DRD4DRD3 | |
| SCHEMBL7139434 | 0.79 | DRD2 (0.47) | DRD2DRD1DRD5DRD4DRD3 | |
| SCHEMBL1276263 | 0.76 | DRD2 (0.56) | DRD2DRD1DRD5DRD4ALDH1A1 | |
| SCHEMBL250734 | 0.69 | CYP2A6 (0.65) | DRD2DRD1DRD5DRD4DRD3 | |
| SCHEMBL12191968 | 0.69 | DRD1 (0.49) | DRD2DRD1DRD5DRD4DRD3 | |
| SCHEMBL1280654 | 0.68 | CD44 (0.48) | DRD2DRD1DRD5DRD4KDM4E | |
| SCHEMBL807459 | 0.66 | MAPT (0.72) | DRD2DRD1DRD5KDM4ENPC1 | |
| SCHEMBL6901150 | 0.66 | DRD1 (0.73) | DRD2DRD1DRD5DRD4DRD3 | |
| SCHEMBL6903685 | 0.66 | DRD1 (0.76) | DRD2DRD1DRD5DRD4DRD3 | |
| SCHEMBL2771201 | 0.65 | CYP2A6 (0.48) | DRD2DRD1DRD5DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265146-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20050187284-A1 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-6933314-B2 | Integrin receptor inhibitors | GENENTECH, INC. (US) | 2005-08-23 | — | — | US | disclosed |
| US-20040077693-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6706753-B2 | 2-AMINO-FLUORENE DERIVATIVES USEFUL FOR PROPHYLACTIC AND/OR THERAPEUTIC TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH ALPHA 4 INTERGRINS OR THEIR LIGANDS | GENENTECH, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1330430-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | GENENTECH, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020035104-A1 | Integrin receptor inhibitors | GENENTECH, INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002016313-A2 | INTEGRIN RECEPTOR INHIBITORS | GENENTECH, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077693-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | DRD2 3328/4885DRD1 3629/4885DRD5 2397/4885 |
| US-20020035104-A1 | Integrin receptor inhibitors | ITGB1, ITGA1, ITGA4 | DRD2 3328/4885DRD1 3629/4885DRD5 2397/4885 |
| US-20050187284-A1 | Integrin receptor inhibitors | ITGA4, ITGB4, ITGB1 | DRD2 3206/4885DRD1 3996/4885DRD5 2227/4885 |
| US-20030100599-A1 | 2-amino-fluorene derivatives useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with alpha 4 intergrins or their ligands | ITGA1, ITGA2, ITGB1 | DRD2 2102/4885DRD1 3050/4885DRD5 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.